If all immunocompromised patients can experience Post Transplantation Lymphoproliferative Disorder (PTLD) due to EBV reactivation, EBV-seronegative recipients in which primary infection can occur, are at higher risk of developing PTLD when transplanted with an organ from an EBV seropositive donor(1,2). In our center, among 73 EBV-seronegative adult patients transplanted between 2000 and 2016 (3% of the whole), 8 developed an early PTLD and 5 others beyond one year, all EBV-related(3). EBV is most often latent and inaccessible within B cells, but occasionally it achieves a lytic infection, susceptible to some antiviral drugs, such as (val)ganciclovir, and specific antibodies.